STEADY-PD III
The Safety, Tolerability, and Efficacy Assessment of Dynacirc® CR for PD (STEADY-PD III) trial was an NINDS funded Phase 3 study evaluating the efficacy of isradipine CR 10mg daily versus placebo (1:1 randomization, double-blind) to slow progression of disability in de novo PD participants. The study was conducted by the Parkinson's Study Group (PSG) at 54 sites in the US and Canada. The investigators found no effect of isradipine treatment on progression of disability or time to onset of motor complications/initiation of dopaminergic therapy in early PD.
Study Participants
336 participants with de novo PD (duration <3 years, not taking dopaminergic therapy at enrollment), were recruited to the study between 2014 and 2015. The retention rate was 95% over the 36-month study.
Available Data
CLINICAL: performance, observational, and self-reported assessments of motor, cognitive, and functional staging
Request access to the de-identified raw dataset through the NINDS data archive
Request access to the PDBP-normalized dataset through the DMR
GENETIC: whole genome sequencing
Available Biospecimens
DNA from blood and plasma